In yesterday’s Wall Street session, ImmunityBio Inc (NASDAQ:IBRX) shares traded at $4.19, up 12.03% from the previous session.
As of this writing, 1 analysts cover ImmunityBio Inc (NASDAQ:IBRX). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $4.00 and a low of $4.00, we find $4.00. Given the previous closing price of $3.74, this indicates a potential upside of 6.95 percent. IBRX stock price is now 86.34% away from the 50-day moving average and 74.46% away from the 200-day moving average. The market capitalization of the company currently stands at $2.80B.
There are 1 analysts who have given it a hold rating, whereas 0 have given it a buy rating. Brokers who have rated the stock have averaged $4.00 as their price target over the next twelve months.
With the price target reduced from $10 to $4, Piper Sandler Downgraded its rating from Overweight to Neutral for ImmunityBio Inc (NASDAQ: IBRX).
In other news, BLASZYK MICHAEL D, Director bought 71,915 shares of the company’s stock on Jun 05. The stock was bought for $198,023 at an average price of $2.75. Upon completion of the transaction, the Director now directly owns 71,915 shares in the company, valued at $0.3 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 02, Director Brennan John Owen bought 25,000 shares of the business’s stock. A total of $70,700 was incurred on buying the stock at an average price of $2.83. This leaves the insider owning 25,000 shares of the company worth $0.1 million. Insiders disposed of 46,465 shares of company stock worth roughly $0.19 million over the past 1 year. A total of 80.41% of the company’s stock is owned by insiders.
Wednesday morning saw ImmunityBio Inc (NASDAQ: IBRX) opened at $3.9200. During the past 12 months, ImmunityBio Inc has had a low of $1.21 and a high of $7.10. The fifty day moving average price for IBRX is $2.2486 and a two-hundred day moving average price translates $2.4017 for the stock.
The latest earnings results from ImmunityBio Inc (NASDAQ: IBRX) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.19, beating analysts’ expectations of -$0.25 by 0.06. This compares to -$0.28 EPS in the same period last year. The company reported revenue of $82000.0 for the quarter, compared to $0.12 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -30.51 percent. For the current quarter, analysts expect IBRX to generate $20k in revenue.
